Sequenom Launches iSEQ Application
Sequenom, Inc. (NASDAQ: SQNM), a leading provider of genetic analysis solutions, today announced the launch of the iSEQ(TM) application software, a MassARRAY(R) comparative sequence analysis application for automated, high-throughput identification and typing of microbes and viruses, as well as human disease-related molecular markers. This product is directed toward the infectious disease market – an area of increasing concern in today’s global public health environment.
The iSEQ application, based on Sequenom’s proprietary MassCLEAVE(TM) biochemistry, enables automatic sample identification, sample grouping and mutation detection by comparison with user-defined reference sequence sets. iSEQ offers a versatile, comprehensive solution for clinical research, outbreak and treatment monitoring, forensics and biodefense, and food safety. Benefits of the application include its high-throughput, ease of use, flexible format and automation of data analysis.
“Human health is constantly challenged by food-borne, sexually transmitted and other pathogens, and institutions like the CDC set global standards on these matters related to human health. The iSEQ application expands Sequenom’s genomic and genetic analysis portfolio into the identification and characterization of infectious disease agents and should set a new standard in molecular typing,” said Harry Stylli, Ph.D., President and CEO of Sequenom. “This important new product could open additional partnering opportunities, as well as introduce Sequenom to new markets and customers.”
An overview of the iSEQ software and fields of application was presented at the 11th Conference in Genomics and Proteomics of Human Pathogens on June 27, 2008, at the Health Protection Agency in London, United Kingdom.
Sequenom is committed to providing the best genetic analysis products that translate the results of genomic science into solutions for biomedical research, translational research and molecular medicine applications, and for research conducted in the agro (agricultural and livestock) industry. The Company’s proprietary MassARRAY system is a high-performance (in speed, accuracy and cost efficiency) DNA analysis platform that quantitatively and precisely measures genetic target material and variations. The Company has exclusively licensed intellectual property rights for the development and commercialization of non-invasive prenatal genetic tests for use with the MassARRAY system and other platforms.
Sequenom(R), iSEQ(TM), MassCLEAVE(TM) and MassARRAY(R) are trademarks of SEQUENOM, Inc.
Except for the historical information contained herein, the matters set forth in this press release, including statements regarding the performance and benefits of the iSEQ application and the Company’s expectations regarding the iSEQ application setting a new standard in molecular typing, developing new methods for rapid genotyping, and additional partnering opportunities and new markets and new customers, are forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including the risks and uncertainties associated with demand for and market acceptance of Sequenom’s products, services, and technologies, including new products such as the iSEQ application, new technology and product development and commercialization, reliance upon the collaborative efforts of other parties, competition, government regulation, obtaining or maintaining regulatory approvals, and other risks detailed from time to time in the Company’s reports filed with the Securities and Exchange Commission. These forward-looking statements are based on current information that is likely to change and speak only as of the date hereof. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement, and Sequenom undertakes no obligation to revise or update any forward-looking statement to reflect events or circumstances after the issuance of this press release.